IDEAYA Biosciences (IDYA) SEC Filings: History & Chart

IDEAYA Biosciences, Inc.(IDYA)

Biotechnology · South San Francisco, CA

$36.63-1.43 (-3.76%)

Delayed quote: Oct 6, 2026, 4:00 PM EDT

About IDEAYA Biosciences, Inc.

IDEAYA Biosciences, Inc. is a precision oncology company primarily dedicated to identifying and advancing targeted therapies, particularly leveraging the concept of synthetic lethality. The firm aims to develop specific treatments for patient groups selected through molecular diagnostic methods. At the forefront of its clinical efforts are two investigational drugs. IDE397, a methionine adenosyltransferase 2a (MAT2A) blocking agent, is currently in early-stage (Phase I) trials for solid tumors exhibiting methylthioadenosine phosphorylase (MTAP) deletions. Its second primary candidate, IDE196, a protein kinase C (PKC) inhibitor, is progressing through Phase I/II studies, targeting genetically defined cancers characterized by GNAQ or GNA11 gene mutations. Beyond its clinical pipeline, IDEAYA's earlier-stage portfolio includes several synthetic lethality programs. These encompass a PARG inhibitor designed to address tumors with specific genetic or molecular biomarkers, Pol Theta inhibitors aimed at cancers presenting with BRCA or other homologous recombination deficiency (HRD) mutations, and WRN inhibitors for tumors demonstrating high microsatellite instability (MSI-H). The company also engages in significant collaborations. It has a joint research effort with Cancer Research UK and the University of Manchester, focusing on small molecule inhibitors of Poly (ADP-ribose) glycohydrolase. Furthermore, IDEAYA maintains a partnership with Pfizer Inc. for the clinical development and supply in Phase I/II trials across metastatic uveal melanoma, skin melanoma, and other solid tumors, alongside a strategic alliance with GlaxoSmithKline plc. IDEAYA Biosciences, Inc. was established in 2015 and operates from its headquarters in South San Francisco, California.

South San Francisco, CA

145 employees

www.ideayabio.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Yujiro S. Hata

View full financials

Form	Filing Date	Accepted	Document
SC 13G	Aug 14, 2026	Aug 14, 2026	View filing
10-Q	Aug 4, 2026	Aug 4, 2026	View filing
8-K	Aug 4, 2026	Aug 4, 2026	View filing
SC 13G	Jul 31, 2026	Jul 31, 2026	View filing
4	Jul 9, 2026	Jul 9, 2026	View filing
8-K	Jun 23, 2026	Jun 23, 2026	View filing
4	Jun 18, 2026	Jun 18, 2026	View filing
4	Jun 18, 2026	Jun 18, 2026	View filing
4	Jun 18, 2026	Jun 18, 2026	View filing
4	Jun 18, 2026	Jun 18, 2026	View filing
4	Jun 18, 2026	Jun 18, 2026	View filing
4	Jun 18, 2026	Jun 18, 2026	View filing
8-K	Jun 10, 2026	Jun 10, 2026	View filing
424B5	Jun 9, 2026	Jun 9, 2026	View filing
424B5	Jun 8, 2026	Jun 8, 2026	View filing
3	Jun 5, 2026	Jun 5, 2026	View filing
8-K	Jun 3, 2026	Jun 3, 2026	View filing
8-K	Jun 1, 2026	Jun 1, 2026	View filing
SC 13G/A	May 15, 2026	May 15, 2026	View filing
8-K	May 5, 2026	May 5, 2026	View filing
424B5	May 5, 2026	May 5, 2026	View filing
S-3ASR	May 5, 2026	May 5, 2026	View filing
10-Q	May 5, 2026	May 5, 2026	View filing
8-K	May 5, 2026	May 5, 2026	View filing
DEFA14A	Apr 30, 2026	Apr 30, 2026	View filing
DEF 14A	Apr 29, 2026	Apr 29, 2026	View filing
ARS	Apr 29, 2026	Apr 29, 2026	View filing
8-K	Apr 13, 2026	Apr 13, 2026	View filing
8-K	Apr 9, 2026	Apr 9, 2026	View filing
SC 13G/A	Mar 27, 2026	Mar 27, 2026	View filing

SEC Filings

Recent Filings